---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-018793"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2024-04-29T23:59:59+00:00"
generated_at: "2026-06-03T05:30:10.648564+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# FDA approves X4 Pharma's XOLREMDI for WHIM syndrome; pricing set at $496,400/yr

## Summary
- XOLREMDI (mavorixafor) approved for WHIM syndrome patients aged 12+ to increase neutrophils and lymphocytes.
- Wholesale acquisition cost: $496,400/yr (patients >50 kg, 400 mg daily) and $372,300/yr (≤50 kg, 300 mg daily).
- Launch through specialty pharmacy PANTHERx Rare; X4Connect support program offers copay assistance and insurance help.
- Corporate presentation posted on company website providing business updates.

## SEC filing metadata
- accession: 0001628280-24-018793
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2024-04-29T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828024018793/0001628280-24-018793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828024018793/xfor-20240429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-018793
- JSON: https://secwatch.observer/filing/0001628280-24-018793.json
- Plain text: https://secwatch.observer/filing/0001628280-24-018793.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.